Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis

Rashmi Kaul, Mohan Shenoy, Elzbieta Goluszko, Premkumar Christadoss

Research output: Contribution to journalArticlepeer-review

75 Scopus citations

Abstract

To analyze the impact of lack of MHC class II gene expression, and to demonstrate the direct genetic evidence for the involvement of the MHC class II gene product in the development of experimental autoimmune myasthenia gravis (EAMG), MHC class II gene-disrupted C57BL6 mutant (-/-) and EAMG- susceptible MHC class II wild-type C57BL6 mice (+/+) were evaluated for the clinical and immunopathologic manifestations of EAMG. The deficiency of MHC class II, and therefore, CD4+ T cells, completely prevented the C57BL6 MHC class II mutant (-/-) mice from mounting an autoimmune response to the nicotinic acetylcholine receptor. Further, the mutant (-/-) mice failed to show any immunopathologic and clinical manifestations of EAMG. The data unequivocally provide direct genetic evidence for the essential role of MHC class II molecules in the induction of EAMG, and rule out any pathogenic effector role for MHC class I-restricted CD8+ T cells, γδ TCR-bearing cells, or NK cells, which are intact in the MHC class II mutant mice in the induction of EAMG.

Original languageEnglish (US)
Pages (from-to)3152-3157
Number of pages6
JournalJournal of Immunology
Volume152
Issue number6
StatePublished - Mar 15 1994

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis'. Together they form a unique fingerprint.

Cite this